Nadunolimab is under clinical development by Cantargia and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer). According to GlobalData, Phase I drugs for Transitional Cell Cancer (Urothelial Cell Cancer) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nadunolimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nadunolimab (CAN-04) is under development for the treatment solid tumours including urothelial cancer, liver cancer, esophageal cancer, head and neck cancer, metastatic non-small cell lung cancer, extrahepatic cholangiocarcinoma, gallbladder cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer, colorectal cancer, bladder cancer, colon cancer, malignant melanoma, metastatic biliary tract cancer, metastatic pancreatic cancer, squamous non-small cell lung cancer and other solid tumors. It is administered by intravenous route. The drug candidate acts by targeting leukemic stem cells by binding to the IL1-RAP receptor. It was also under development for acute lymphocytic leukaemia, and chronic myelocytic leukaemia.
Cantargia, a subsidiary of Lund University Bioscience AB is a biotechnology company that develops antibody-based cancer treatments. The company’s product candidate CAN04 is used for the treatment of cancers including non-small cell lung cancer and pancreatic cancer. It utilizes cell surface receptors as a target to develop a novel antibody-based therapy for the treatment of chronic myeloid leukemia and other forms of leukemia. Cantargia provides therapies for the treatment of hematological malignancies that uses the expression of cell surface receptor on hematopoietic stem cells. The company also develops antibody therapeutics to eradicate leukemia disease-causing stem cells. Cantargia is headquartered in Lund, Sweden.
For a complete picture of Nadunolimab’s drug-specific PTSR and LoA scores, buy the report here.